The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy
Open accessAbstract
Angiogenesis has not been extensively studied in Parkinson's disease (PD) despite being associated with other neurodegenerative disorders. Post-mortem human brain tissues were obtained from subjects with pathologically confirmed Parkinson's disease (PD) and progressive supranuclear palsy (PSP), a rapidly progressing Parkinsonian-like disorder. Tissues were also obtained from subjects with incidental Lewy body disease (iLBD) who had Lewy bodies in the substantia nigra pars compacta (SN(pc)) but had not been diagnosed with PD, and age-matched controls without Lewy body pathology. The SNpc, putamen, locus ceruleus (LC) and midfrontal cortex were examined for integrin αvβ3, a marker for angiogenesis, along with vessel number and activated microglia. All parkinsonian syndromes had greater αvβ3 in the LC and the SN(pc), while only PD and PSP subjects had elevated αvβ3 in the putamen compared to controls. PD and PSP subjects also had increases in microglia number and activation in the SN(pc) suggesting a link between inflammation and clinical disease. Microglia activation in iLBD subjects was limited to the LC, an area involved at an early stage of PD. Likewise, iLBD subjects did not differ from controls in αvβ3 staining in the putamen, a late area of involvement in PD. The presence of αvβ3 reactive vessels in PD and its syndromes is indicative of newly created vessels that have not likely developed the restrictive properties of the blood brain barrier. Such angiogenic vessels could contribute to neuroinflammation by failing to protect the parenchyma from peripheral immune cells and inflammatory or toxic factors in the peripheral circulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Aberrant angiogenesis is frequently observed in PD patients, as shown in the substantia nigra pars compacta, locus coeruleus, and putamen (144, 627).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [144]
In the citing paper
“Several studies have identified increased microglia number and activation in the substantia nigra pars compacta (SNpc),372 subthalamic nucleus,373 pyramidal, extrapyramidal motor system, and cerebellar output374 of brain tissues from PSP patients by immunochemical postmortem analysis.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [372]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,594
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Self-citationProgressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Cited by
Sorted by citations
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
The blood–brain barrier in health and disease
Daneman, R. (2012) · Annals of Neurology · doi:10.1002/ana.23648 · Cited by 794
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 481
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 379
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
Cenci, M. A. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00242 · Cited by 250
Inflammation in Parkinson's Disease
Tüfekçi, K. U., Meuwissen, R. L. J., Genç, Ş., & Genç, K. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398314-5.00004-0 · Cited by 205
Vascular Degeneration in Parkinson's Disease
Guan, J., Pavlovic, D., Dalkie, N., Waldvogel, H. J., O'Carroll, S. J., Green, C. R., & Nicholson, L. F. B. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00628.x · Cited by 191
Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
Araújo, B., Caridade-Silva, R., Soares-Guedes, C., Martins‐Macedo, J., Gomes, E. D., Monteiro, S., & Teixeira, F. G. (2022) · Cells · doi:10.3390/cells11182908 · Cited by 209
Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells
Garretti, F., Agalliu, D., Arlehamn, C. S. L., Sette, A., & Sulzer, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00303 · Cited by 171
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 174
Increased CSF biomarkers of angiogenesis in Parkinson disease
Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002151 · Cited by 150
Blood-CNS Barrier Impairment in ALS patients versus an animal model
Garbuzova-Davis, S. N., & Sanberg, P. R. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00021 · Cited by 152
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease
Lee, J., Martín‐Bastida, A., Murueta‐Goyena, A., Gabilondo, I., Cuenca, N., Piccini, P. P., & Jeon, B. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00618-9 · Cited by 132
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Elabi, O. F., Gaceb, A., Carlsson, R., Padel, T., Soylu-Kucharz, R., Cortijo, I., Li, W., Li, J., & Paul, G. (2021) · Scientific Reports · doi:10.1038/s41598-020-80889-8 · Cited by 131
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease
Koeglsperger, T., Rumpf, S.-L., Schließer, P., Struebing, F. L., Brendel, M., Levin, J., Trenkwalder, C., Höglinger, G. U., & Herms, J. W. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00622-7 · Cited by 145
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis
Girolamo, F., Coppola, C., Ribatti, D., & Trojano, M. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0084-z · Cited by 127
Jacquet, A. D. R., Alpaugh, M., Denis, H. L., Tancredi, J. L., Boutin, M. E., Decaestecker, J., Beauparlant, C., Herrmann, L., Saint‐Pierre, M., Parent, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39038-8 · Cited by 126
Microglial interactions with the neurovascular system in physiology and pathology
Zhao, X., Eyo, U. B., Murugan, M., & Wu, L. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22576 · Cited by 112
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 104
Xue, C., Li, X., Ba, L., Zhang, M., Yang, Y., Gao, Y., Sun, Z., Han, Q., & Zhao, R. C. (2021) · Aging and disease · doi:10.14336/ad.2020.1221 · Cited by 100
Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Lee, H. (2014) · Frontiers in bioscience · doi:10.2741/4206 · Cited by 96
Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit
Paul, G., & Elabi, O. F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853372 · Cited by 98
Neuroinflammatory Responses and Parkinson’ Disease: Pathogenic Mechanisms and Therapeutic Targets
Yang, L., Mao, K., Yu, H., & Chen, J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09926-7 · Cited by 91
Blood–brain barrier endothelial cells in neurodegenerative diseases: Signals from the “barrier”
Yuan, Y., Sun, J., Dong, Q., & Cui, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1047778 · Cited by 90
Red/near-infrared irradiation therapy for treatment of central nervous system injuries and disorders
Fitzgerald, M., Hodgetts, S. I., van den Heuvel, C., Natoli, R., Hart, N. S., Valter, K., Harvey, A. R., Vink, R., Provis, J. M., & Dunlop, S. A. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0086 · Cited by 80
López‐Cerdán, A., Andreu, Z., Hidalgo, M. R., Grillo-Risco, R., Català-Senent, J. F., Soler-Sáez, I., Neva-Alejo, A., Gordillo, F., de la Iglesia-Vayá, M., & Garcia‐García, F. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00477-5 · Cited by 77
Ohlin, K. E., Sebastianutto, I., Adkins, C. E., Lundblad, C., Lockman, P. R., & Cenci, M. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.066 · Cited by 77
Small Vessels Are a Big Problem in Neurodegeneration and Neuroprotection
Erdener, Ş. E., & Dalkara, T. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00889 · Cited by 78
Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 77
Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels
Bogorad, M. I., DeStefano, J. G., Linville, R. M., Wong, A. D., & Searson, P. C. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19855875 · Cited by 79
Olmedo‐Díaz, S., Estévez-Silva, H. M., Orädd, G., af Bjerkén, S., Marcellino, D. J., & Virel, A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.023 · Cited by 71
Padel, T., Özen, I., Boix, J., Barbariga, M., Gaceb, A., Roth, M., & Paul, G. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.002 · Cited by 70
Muñoz, A., Garrido‐Gil, P., Dominguez‐Meijide, A., & Labandeira-García, J. L. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.08.019 · Cited by 71
Armentero, M., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 75
Alster, P., Madetko‐Alster, N., Koziorowski, D., & Friedman, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00893 · Cited by 68
Iron Deposition in Parkinson’s Disease: A Mini-Review
Zeng, W., Cai, J., Zhang, L., & Peng, Q. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01459-4 · Cited by 64
Bogale, T. A., Faustini, G., Longhena, F., Mitola, S. M. F., Pizzi, M., & Bellucci, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611761 · Cited by 61
Kaur, G., Behl, T., BUNGAU, S. G., Kumar, A., Uddin, M. S., Mehta, V., Zengin, G., Mathew, B., Shah, M. A., & Arora, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606233050 · Cited by 57
Elabi, O. F., da Cunha, J. P. M. C. M., Gaceb, A., Fex, M., & Paul, G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02218-8 · Cited by 58
The Role of the Vascular System in Degenerative Diseases: Mechanisms and Implications
Sheikh, A. M., Yano, S., Tabassum, S., & Nagai, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042169 · Cited by 64
Brain barriers in health and disease
Daneman, R., & Engelhardt, B. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.008 · Cited by 51
Dysfunction of the neurovascular unit in diabetes-related neurodegeneration
Yan, C., Zhou, Y., Chen, Q., Luo, Y., Zhang, J. H., Huang, H., & Shao, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110656 · Cited by 47
The avascular zone and neuronal remodeling of the fovea in Parkinson disease
Miri, S., Shrier, E. M., Glazman, S., Ding, Y., Selesnick, I., Kozlowski, P. B., & Bodis-Wollner, I. G. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.146 · Cited by 42
Bastos, P. A. D., Ferreira, R. M., Manadas, B. J., Moreira, P. I., & Vitorino, R. M. P. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1299682 · Cited by 40
Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 43
Subvoxel vascular imaging of the midbrain using USPIO-Enhanced MRI
Buch, S., Wang, Y., Park, M., Jella, P. K., Hu, J., Chen, Y., Shah, K., Ge, Y., & Haacke, E. M. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117106 · Cited by 38
Foveal Remodeling of Retinal Microvasculature in Parkinson’s Disease
Murueta‐Goyena, A., Barrenechea, M., Erramuzpe, A., Teijeira‐Portas, S., Pengo, M., Ayala, U., Romero-Bascones, D., Acera, M., Pino, R. D., Gómez‐Esteban, J. C., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708700 · Cited by 39
Vascular, flow and perfusion abnormalities in Parkinson's disease
Zhang, C., Wu, B., Wang, X., Chen, C., Zhao, R.-C., Lu, H., Zhu, H., Xue, B., Liang, H., Sethi, S. K., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.02.019 · Cited by 37
T cells, α-synuclein and Parkinson disease
Garretti, F., Monahan, C., Sette, A., Agalliu, D., & Sulzer, D. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00023-0 · Cited by 39
Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP
Miguel, M. S., Martin, K. L., Stone, J., & Johnstone, D. M. (2019) · Biomolecules · doi:10.3390/biom9100564 · Cited by 37
McCarthy, C. A., Widdop, R. E., Deliyanti, D., & Wilkinson‐Berka, J. L. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12099 · Cited by 36
Khor, S. L. Q., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330093829 · Cited by 37
Is brain gliosis a characteristic of chronic methamphetamine use in the human?
Tong, J., Fitzmaurice, P. S., Furukawa, Y., Schmunk, G. A., Wickham, D. J., Ang, L.-C., Sherwin, A. L., McCluskey, T., Boileau, I., & Kish, S. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.015 · Cited by 35
Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease
Zhou, Y., Cheng-zhi, G., Li, J., Zhu, L., Huang, G., Dai, J., & Huaiyu, H. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s178435 · Cited by 32
Behl, T., Kaur, G., BUNGAU, S. G., Jhanji, R., Kumar, A., Mehta, V., Zengin, G., Brata, R. D., Hassan, S. S. U., & Frățilă, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176235 · Cited by 34
Glycation: The angiogenic paradox in aging and age-related disorders and diseases
Roca, F., Grossin, N., Chassagne, P., Puisieux, F. L., & Boulanger, É. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.009 · Cited by 35
Chen, C.-C. V., Chen, Y., Hsiao, H., Chang, C., & Chern, Y. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-47 · Cited by 32
Pramotton, F. M., Spitz, S., & Kamm, R. D. (2024) · Advanced Science · doi:10.1002/advs.202403892 · Cited by 33
Song, W.-S., Sung, C.-Y., Ke, C., & Yang, F. (2021) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2021.10.001 · Cited by 31
LncRNAs as putative biomarkers and therapeutic targets for Parkinson’s disease
Taghizadeh, E., Hayat, S. M. G., Taheri, F., Afshani, S. M. R., Farahani, N., & Saberi, A. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05408-7 · Cited by 30
Endothelial Senescence and Its Impact on Angiogenesis in Alzheimer’s Disease
Georgieva, I., Tchekalarova, J. D., Iliev, D. B., & Tzoneva, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411344 · Cited by 29
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Fowler, A. J., Ahn, J., Hebron, M., Chiu, T., Ayoub, R., Mulki, S., Ressom, H., Torres-Yaghi, Y., Wilmarth, B., Pagan, F. L., et al. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000633 · Cited by 29
Progressive Supranuclear Palsy Syndrome: An Overview
Ichikawa-Escamilla, E., Velasco-Martínez, R. A., & Adalid-Peralta, L. V. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.04.008 · Cited by 31
Eve, D. J., Steiner, G. A., Mahendrasah, A., Sanberg, P. R., Kurien, C., Thomson, A., Borlongan, C. V., & Garbuzova-Davis, S. N. (2018) · Oncotarget · doi:10.18632/oncotarget.24360 · Cited by 26
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 24
Kolinko, Y., Krakorová, K., Cendelín, J., Tonar, Z., & Králíčková, M. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0049 · Cited by 28
Sharma, P. K., Kishore, A., De, I., Negi, S., Kumar, G., Bhardwaj, S., & Singh, M. P. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105604 · Cited by 24
Zedde, M., & Pascarella, R. (2024) · Brain Sciences · doi:10.3390/brainsci14100983 · Cited by 21
Imaging Parkinsonian Pathology in Substantia Nigra with MRI
Huddleston, D. E., Langley, J. A., Dušek, P., He, N., Faraco, C. C., Crosson, B., Factor, S. A., & Hu, X. P. (2018) · Current Radiology Reports · doi:10.1007/s40134-018-0272-x · Cited by 21
Olofsson, H. E., & Englund, E. M. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12552 · Cited by 22
The role of reactive oxygen species in the regulation of the blood-brain barrier
Shuvalova, M. L., Dmitrieva, A., Belousov, V. V., & Nosov, G. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2361202 · Cited by 21
Bisht, I., Ambasta, R. K., & Kumar, P. (2020) · Neuropeptides · doi:10.1016/j.npep.2020.102078 · Cited by 20
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia
Jourdain, V. A., Schindlbeck, K. A., Tang, C. C., Niethammer, M., Choi, Y. Y., Markowitz, D. M., Nazem, A., Nardi, D., Carras, N. G., Feigin, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.96411 · Cited by 20
Sánchez‐Ruiz de Gordoa, J., Erro, M. E., Vicuña‐Urriza, J., Zelaya, M. V., Tellechea, P., Acha, B., Zueco, S., Urdánoz‐Casado, A., Roldán, M., Blanco‐Luquin, I., et al. (2020) · Movement Disorders · doi:10.1002/mds.27992 · Cited by 18
Impaired cerebral microcirculation in isolated REM sleep behaviour disorder
Eskildsen, S. F., Iranzo, Á., Stokholm, M. G., Stær, K., Østergaard, K., Serradell, M., Otto, M., Svendsen, K. B., Garrido, A., Vilas, D., et al. (2021) · Brain · doi:10.1093/brain/awab054 · Cited by 15
Shihabuddeen, W. A., Yu, R. M. C., Pan, Y., Iwata, T., Barathi, V. A., Wey, Y. S., Tun, S. B. B., Qiu, B., Tan, A., Wang, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810206 · Cited by 14
Shibata, S., Ishitobi, H., Miyaki, S., Kawaoka, T., Kayashima, T., & Matsubara, K. (2016) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2016.1208734 · Cited by 14
Guo, X., Wei, R., Yin, X., & Yang, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528538 · Cited by 13
The STRAT-PARK cohort: A personalized initiative to stratify Parkinson’s disease
Stige, K. E., Kverneng, S. U., Sharma, S., Skeie, G. O., Sheard, E., Søgnen, M., Geijerstam, S. A. A., Vetås, T., Wahlvåg, A. G., Berven, H., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102603 · Cited by 14
Farhoudi, M., Sadigh‐Eteghad, S., Mahmoudi, J., Farjami, A., Mahmoudian, M., & Salatin, S. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220608093639 · Cited by 13
Reuck, J. L. D., Auger, F., Durieux, N., Cordonnier, C., Deramecourt, V., Lebert, F., Leys, D., Pasquier, F., Maurage, C., & Bordet, R. (2015) · European Neurology · doi:10.1159/000441057 · Cited by 13
Wu, C., Wang, S.-E., Lin, C.-L., Hsu, C.-H., Sheu, S.-J., & Chien, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s78015 · Cited by 12
Salmina, A. B., Komleva, Y. K., Malinovskaya, N. A., Morgun, A. V., Тепляшина, Е. А., Lopatina, O. L., Gorina, Y. V., Kharitonova, E. V., Хилажева, Е. Д., & Shuvaev, А. N. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921060122 · Cited by 12
Ishihara, K., Takata, K., & Mizutani, K. (2023) · Life · doi:10.3390/life13010221 · Cited by 10
Joseph, S., Robbins, C. B., Allen, A., Haystead, A., Hemesath, A., Kundu, A., Ma, J. P., Johnson, K. G., Agrawal, R. V., Gunasan, V., et al. (2023) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264231206607 · Cited by 9
Albanese, G. M., Gharbiya, M., Visioli, G., Panigutti, M., Margarella, A., Romano, E., Mastrogiuseppe, E., Sepe‐Monti, M., Bruno, G., & D’Antonio, F. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07683-6 · Cited by 9
Neuroinflammation in Movement Disorders
Saavedra-López, E., Casanova, P. V., Cribaro, G. P., & Barcia, C. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00038-6 · Cited by 9
Reuck, J. D., Caparros-Lefebvre, D., Deramecourt, V., Defebvre, L., Auger, F., Durieux, N., Bordet, R., Pasquier, F., & Maurage, C. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.47843 · Cited by 7
Druggable targets for Parkinson’s disease: transcriptomics based Mendelian randomization study
Lyu, Q., Chen, R., Qiu, Z., Wang, C., & Liu, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-77401-x · Cited by 9
Angelopoulou, E., Paudel, Y. N., & Piperi, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02326-9 · Cited by 6
Alalykina Elena, S., Sergeyeva, T., Ananyan Michail, A., Анатольевич, Ч. И., & Sergeev Valeriy, G. (2024) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001092 · Cited by 5
Jeong, J.-Y., Lee, H. J., Kim, N., Li, Y., Rah, J., & Oh, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-49900-w · Cited by 6
Reuck, J. D., Auger, F., Durieux, N., Deramecourt, V., Maurage, C., Lebert, F., Leys, D., Cordonnier, C., Pasquier, F., & Bordet, R. (2016) · Folia Neuropathologica · doi:10.5114/fn.2016.60364 · Cited by 5
Metadata
- Authors
- Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., & Hendey, B.
- Affiliations
- Rush University (US)
- Corresponding author
- Hendey, Bill
- ORCID
- Schneider, Julie A.
- Venue
- Journal of Neural Transmission
- Published
- 2011-07-12
- Volume
- 119
- Issue
- 1
- Pages
- 59-71
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- PMC
- PMC3352316
- OpenAlex
- W1968306269
- Cited by
- 139
- References
- 90
- Citations by year
- 2026: 10 · 2025: 4 · 2024: 14 · 2023: 10 · 2022: 11 · 2021: 19 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 5 · 2016: 10 · 2015: 7 · 2014: 10 · 2013: 3 · 2012: 4
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (P30-AG 10161, R01 AG15819, R01AG015819, P30AG010161, K08AG000849, K08AG000848)
- National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
- National Institute of Neurological Disorders and Stroke (NS052414, R01NS052414)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- angiogenesis, Parkinson's disease, incidental Lewy body disease, progressive supranuclear palsy, integrin αvβ3, microglial activation, neuroinflammation, blood-brain barrier, locus coeruleus, substantia nigra pars compacta, putamen, Lewy bodies
- MeSH terms
- Aged, Aged, 80 and over, Analysis of Variance, Brain, Female, Humans, Male, Neovascularization, Pathologic, Neurons, Parkinson Disease, Postmortem Changes, Supranuclear Palsy, Progressive, Microglia, Lewy Body Disease, Integrin alphaVbeta3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
